Ethyol Approved for Use in the UK

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatory agency for the United Kingdom, has granted a product license for the marketing of Ethyol (amifostine), manufactured by U.S. Bioscience, Inc.

WEST CONSHOHOCKEN, Pa--The Medicines Control Agency, the regulatoryagency for the United Kingdom, has granted a product license forthe marketing of Ethyol (amifostine), manufactured by U.S. Bioscience,Inc.

Ethyol is a selective cytoprotective agent indicated for the reductionof neutropenia-related infection resulting from use of the combinationof cyclophosphamide (Cytoxan, Neosar) and cisplatin (Platinol)in patients with advanced ovarian carcinoma.

Approval of ethyol in this country suffered a set back when anadvisory committee failed to recommend it to the FDA.

Articles in this issue
MDs Fear Managed Care Equals Lower-Quality Care
Dallas Medical Center Launches Umbilical Stem Cell Project
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Cancer
European Trials Show Dose-Related Efficacy of Docetaxel In Metastatic Breast Cancer, Value of Steroid Pretreatment
Ethyol Approved for Use in the UK
Success of Breast Conserving Surgery Is Not Diminished in Community Setting
Assessment Tools Are Essential to Improve Management of Pain
Undertreating Pain Costs Money in the Long Run, Physician Warns
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCI
EORTC Endometrial Ca Trial Challenges Findings From GOG
Heterosexual AIDS Cases Up Sharply, But Numbers Remain Small
Antibiotic Regimen Leads to Lymphoma Regression
Look for Incremental Insurance Reform Steps With New Congress
Court Upholds Patents on AZT
Advances Reported in Phase I/II Trials of Radioimmunotherapy for Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
4 experts in this video
4 experts in this video
2 experts in this video
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
6371178759112
Related Content
Post AHSCT Palliative Care Survey Shows Patient Needs, Clinician Perceptions Differ

Post AHSCT Palliative Care Survey Shows Patient Needs, Clinician Perceptions Differ

Tim Cortese
April 11th 2025
Article

The Integrated Palliative Care Outcome Scale showed the potential to guide palliative care integration to better help patients and clinicians after AHSCT.

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

107 Neratinib-Based Combination Treatments for Patients With HER2-Positive Breast Cancer Brain Metastases

Sarah Sammons;Rachel A. Freedman;Adam M. Brufsky;Ahmad Awada;Sara A. Hurvitz, MD;Nancy U. Lin, MD;Cristina Saura;Sheri Leung;Bethann S Hromatka
April 9th 2025
Podcast
A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

Most Oncology Nurses Feel Their Post-Pandemic Workload Has Increased

Roman Fabbricatore
April 10th 2025
Article

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Bevacizumab Biosimilar Approved for Intravenous Use in Solid Tumors

Tim Cortese
April 10th 2025
Article

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Real-world data may support a new way to consider follow-up treatment for patients who are elderly with extensive-stage small cell lung cancer.

Chemoimmunotherapy Elicits Survival Benefit in Older ES-SCLC Population

Russ Conroy
April 10th 2025
Article

Real-world data may support a new way to consider follow-up treatment for patients who are older with extensive-stage small cell lung cancer.